This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Pharmaceuticals, Medical Devices and Other Therapeutic Products Act | |
|---|---|
| Name | Pharmaceuticals, Medical Devices and Other Therapeutic Products Act |
| Long name | Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices and Other Therapeutic Products |
| Enacted by | National Diet |
| Enacted | 1960s–2010s |
| Status | in force |
Pharmaceuticals, Medical Devices and Other Therapeutic Products Act The Pharmaceuticals, Medical Devices and Other Therapeutic Products Act is a Japanese statute that governs the regulation of medicines, medical devices, and related therapeutic products. It consolidates regulatory functions historically distributed among multiple ministries and agencies to ensure product quality, efficacy, and safety for patients across Tokyo, Osaka, Sapporo, Nagoya. The Act interfaces with international frameworks represented by World Health Organization, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Pharmaceutical Research and Manufacturers of America, European Medicines Agency, United States Food and Drug Administration.
The Act emerged from reforms initiated after postwar public health incidents and administrative reorganizations involving Ministry of Health, Labour and Welfare (Japan), Ministry of Trade and Industry (Japan), Ministry of Education, Culture, Sports, Science and Technology (Japan), and advisory bodies such as the Central Social Insurance Medical Council. Early pharmaceutical statutes trace to the Meiji period legal modernization and health policy debates paralleling reforms in United Kingdom, Germany, France, and United States regulatory histories. Major revisions followed high-profile cases invoking scrutiny by Tokyo District Court and investigations by parliamentary committees of the National Diet, leading to amendments aligning domestic law with standards promoted by World Health Organization and trade partners including Australia, Canada, China, South Korea.
The Act defines regulated items across pharmaceutical, medical device, and other therapeutic product categories, referencing classification systems used by International Medical Device Regulators Forum, ISO, IEC. Key definitions distinguish pharmaceuticals, biological products, in vitro diagnostics, combination products, and regenerative medicine products linked to institutions such as Riken, Kyoto University, Osaka University, Keio University. The Act sets out definitions for marketing authorization holders, manufacturers, importers, and distributors, aligning terminology with agreements negotiated through World Trade Organization fora and bilateral talks with United States, European Union, ASEAN partners.
Primary regulatory authority under the Act is the Pharmaceuticals and Medical Devices Agency (Japan), operating under the policy oversight of the Ministry of Health, Labour and Welfare (Japan). The framework incorporates review, inspection, and approval functions comparable to United States Food and Drug Administration, European Medicines Agency, Health Canada, Therapeutic Goods Administration (Australia). Adjudicative and advisory roles involve panels drawing expertise from Japan Society for Regenerative Medicine, Japanese Pharmacological Society, Japan Medical Association, and academic centers such as University of Tokyo Hospital and Tohoku University Hospital.
Approval pathways require submission of clinical data, nonclinical studies, and manufacturing information consistent with guidelines from International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Good Clinical Practice, Good Manufacturing Practice, and standards referenced by ISO. The Act provides for expedited review mechanisms for orphan drugs, emergency use authorization during public health emergencies declared by Ministry of Health, Labour and Welfare (Japan), and conditional approvals for regenerative medicine similar to pathways used by United States Food and Drug Administration and European Medicines Agency. Applicants typically interact with regulatory reviewers from Pharmaceuticals and Medical Devices Agency (Japan), and dossier assessments often consider precedents from approvals in United States, European Union, Australia, Canada.
Post-marketing obligations under the Act include adverse event reporting, risk management plans, and periodic safety updates coordinated with pharmacovigilance systems akin to EudraVigilance and FDA Adverse Event Reporting System. The Act mandates inspections at manufacturing sites including facilities accredited under Good Manufacturing Practice and empowers the Pharmaceuticals and Medical Devices Agency (Japan) to issue safety communications, recalls, and field safety corrective actions in coordination with prefectural health authorities on matters that may affect beneficiaries of the Japanese National Health Insurance system.
Enforcement mechanisms include administrative sanctions, product suspensions, revocation of approvals, criminal penalties, and injunctive remedies pursued through courts such as the Tokyo District Court and Supreme Court of Japan when violations implicate public safety or consumer protection laws. The Act authorizes inspections by regulatory officers and cooperation with international enforcement initiatives involving agencies like Interpol for cross-border counterfeit investigations, and cooperative compliance programs modeled after FDA Warning Letter practices and European Medicines Agency transparency initiatives.
The Act has modernized regulatory oversight in Japan and facilitated international harmonization with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and trade partners such as United States, European Union, China. Critics including academic commentators at University of Tokyo, patient advocacy groups like Japanese Consumer Affairs Agency-affiliated organizations, and industry associations including Japan Pharmaceutical Manufacturers Association have cited concerns about review timelines, transparency of advisory committee deliberations, and the balance between expedited access and long-term safety monitoring. Debates continue in venues such as the National Diet (Japan) and professional conferences hosted by Japan Clinical Oncology Group regarding amendments to address emerging fields like gene therapy, regenerative medicine, and digital therapeutics developed by firms collaborating with Sony, Fujifilm, and Hitachi.
Category:Pharmaceutical law